Literature DB >> 29679849

Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015).

Fatima Cardoso1, Danielle Spence2, Shirley Mertz3, Dian Corneliussen-James4, Kimberly Sabelko5, Julie Gralow6, Maria-João Cardoso7, Fedro Peccatori8, Diego Paonessa9, Ann Benares10, Naomi Sakurai11, Marc Beishon12, Sarah-Jane Barker13, Musa Mayer14.   

Abstract

Approximately 0.5 million people worldwide die from metastatic breast cancer (mBC) every year. This manuscript provides an overview on the status of mBC in several regions of the world, highlighting the gaps in care, resources, and support available for patients with mBC. Primary research was conducted in 2015 and 2016, comprising four global qualitative and quantitative surveys of approximately 15,000 individuals in 34 countries. Secondary research was conducted using literature reviews of peer-reviewed publications, patient survey reports, and media or online articles. There have been modest improvements in mBC outcomes over the past decade. Patients are not provided with adequate information about mBC. There is a need for open discussion with patients and caregivers about realistic goals; however, physicians are not trained in communicating with patients about their disease. Maintaining patients' quality of life is a crucial goal; however, this has not improved, and in some cases, may have declined in the past decade. Public awareness and understanding of mBC is limited, with damaging consequences for patients and caregivers. Issues affecting employment remain relevant to patients with mBC and their caregivers. Globally, mBC is associated with a substantial economic burden. Relationships with caregivers are crucial to patients with mBC, and caregiver support needs are often overlooked. A strong and united global effort among healthcare professionals, including clinicians, oncologists, pharmaceutical manufacturers, payers, and policy makers, and with advocates, families, and patients, is necessary to improve the outcome and quality of life for patients with mBC.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Advanced breast cancer; Global analysis; Metastatic breast cancer

Mesh:

Year:  2018        PMID: 29679849     DOI: 10.1016/j.breast.2018.03.002

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  58 in total

1.  4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Authors:  F Cardoso; E Senkus; A Costa; E Papadopoulos; M Aapro; F André; N Harbeck; B Aguilar Lopez; C H Barrios; J Bergh; L Biganzoli; C B Boers-Doets; M J Cardoso; L A Carey; J Cortés; G Curigliano; V Diéras; N S El Saghir; A Eniu; L Fallowfield; P A Francis; K Gelmon; S R D Johnston; B Kaufman; S Koppikar; I E Krop; M Mayer; G Nakigudde; B V Offersen; S Ohno; O Pagani; S Paluch-Shimon; F Penault-Llorca; A Prat; H S Rugo; G W Sledge; D Spence; C Thomssen; D A Vorobiof; B Xu; L Norton; E P Winer
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

Review 2.  Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.

Authors:  Georgia Gomatou; Ioannis Trontzas; Stephanie Ioannou; Maria Drizou; Nikolaos Syrigos; Elias Kotteas
Journal:  Mol Biol Rep       Date:  2021-01-07       Impact factor: 2.316

Review 3.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

Review 4.  MicroRNAs as therapeutic targets in breast cancer metastasis.

Authors:  Fahima Danesh Pouya; Yousef Rasmi; Maria Gazouli; Eleni Zografos; Mohadeseh Nemati
Journal:  Drug Deliv Transl Res       Date:  2021-05-13       Impact factor: 4.617

5.  Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer.

Authors:  Weipeng Zhao; Linlin Sun; Guolei Dong; Xiaorui Wang; Yan Jia; Zhongsheng Tong
Journal:  Ther Adv Med Oncol       Date:  2021-05-06       Impact factor: 8.168

6.  The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.

Authors:  Lingmi Hou; Mengxue Qiu; Maoshan Chen; Fangfang Li; Junyan Li; Shishan Deng; Yahan Yang; Zhenggui Du; Hongwei Yang
Journal:  Gland Surg       Date:  2021-06

7.  Predictive value of lncRNA LOC100505851 in breast cancer in the neoadjuvant setting.

Authors:  Rui Sha; Ziping Wu; Yaqian Xu; Xiaonan Sheng; Yaohui Wang; Chenwei Yuan; Jing Peng; Shuguang Xu; Liheng Zhou; Yanping Lin; Wenjin Yin; Jinsong Lu
Journal:  Gland Surg       Date:  2021-06

8.  PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.

Authors:  Javier Cortés; Violeta Serra; Albert Gris-Oliver; Yasir H Ibrahim; Martín A Rivas; Celina García-García; Mònica Sánchez-Guixé; Fiorella Ruiz-Pace; Cristina Viaplana; José M Pérez-García; Antonio Llombart-Cussac; Judit Grueso; Mireia Parés; Marta Guzmán; Olga Rodríguez; Pilar Anton; Patricia Cozar; Maria Teresa Calvo; Alejandra Bruna; Joaquín Arribas; Carlos Caldas; Rodrigo Dienstmann; Paolo Nuciforo; Mafalda Oliveira
Journal:  Br J Cancer       Date:  2021-03-15       Impact factor: 7.640

Review 9.  Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach.

Authors:  Marloes E Clarijs; Jacob Thurell; Friedrich Kühn; Carin A Uyl-de Groot; Elham Hedayati; Maria M Karsten; Agnes Jager; Linetta B Koppert
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  Access to systemic anti-cancer therapies for women with secondary breast cancer-protocol for a mixed methods systematic review.

Authors:  Sally Anne Pearson; Sally Taylor; Antonia Marsden; Janelle Yorke
Journal:  Syst Rev       Date:  2021-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.